New Mitral Frontier 🚪🫀🚶♂️ TMVR Opens a Third Pathway
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A new era for complex mitral regurgitation.
The ENCIRCLE pivotal trial in The Lancet reports that fully percutaneous, transfemoral, transseptal TMVR (SAPIEN M3) achieved durable MR reduction (≈96% ≤1+ at 1 year), low early mortality, and meaningful improvement in symptoms and quality of life for patients unsuitable for surgery or TEER.
A third pathway for mitral disease is emerging—one built on precision access, valve-in-valve durability planning, and advancing patient selection.
Innovation meeting clinical need. 🚀🫀📈